GtoPdb v.2023.1中的食欲素受体

Gary Aston-Jones, Pascal Bonaventure, Paul Coleman, Luis De Lecea, Debbie Hartman, Daniel Hoyer, Laura Jacobson, Thomas Kilduff, Jyrki P. Kukkonen, Terrence P. McDonald, Rod Porter, John Renger, Takeshi Sakurai, Jerome M Siegel, Gregor Sutcliffe, Neil Upton, Christopher J. Winrow, Masashi Yanagisawa
{"title":"GtoPdb v.2023.1中的食欲素受体","authors":"Gary Aston-Jones, Pascal Bonaventure, Paul Coleman, Luis De Lecea, Debbie Hartman, Daniel Hoyer, Laura Jacobson, Thomas Kilduff, Jyrki P. Kukkonen, Terrence P. McDonald, Rod Porter, John Renger, Takeshi Sakurai, Jerome M Siegel, Gregor Sutcliffe, Neil Upton, Christopher J. Winrow, Masashi Yanagisawa","doi":"10.2218/gtopdb/f51/2023.1","DOIUrl":null,"url":null,"abstract":"Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [43]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [117]. Orexin signaling has been associated with regulation of sleep and wakefulness, reward and addiction, appetite and feeding, pain gating, stress response, anxiety and depression. Currently the orexin receptor ligands in clinical use are the dual orexin receptor antagonists suvorexant and lemborexant and daridorexant, which are used as hypnotics, and several dual and OX2-selective antagonists are under development. Multiple orexin agonists are in development for the treatment of narcolepsy and other sleep disorders. Orexin receptor 3D structures have been solved [146, 144, 55, 126, 47, 109, 7, 145].","PeriodicalId":14617,"journal":{"name":"IUPHAR/BPS Guide to Pharmacology CITE","volume":"09 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Orexin receptors in GtoPdb v.2023.1\",\"authors\":\"Gary Aston-Jones, Pascal Bonaventure, Paul Coleman, Luis De Lecea, Debbie Hartman, Daniel Hoyer, Laura Jacobson, Thomas Kilduff, Jyrki P. Kukkonen, Terrence P. McDonald, Rod Porter, John Renger, Takeshi Sakurai, Jerome M Siegel, Gregor Sutcliffe, Neil Upton, Christopher J. Winrow, Masashi Yanagisawa\",\"doi\":\"10.2218/gtopdb/f51/2023.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [43]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [117]. Orexin signaling has been associated with regulation of sleep and wakefulness, reward and addiction, appetite and feeding, pain gating, stress response, anxiety and depression. Currently the orexin receptor ligands in clinical use are the dual orexin receptor antagonists suvorexant and lemborexant and daridorexant, which are used as hypnotics, and several dual and OX2-selective antagonists are under development. Multiple orexin agonists are in development for the treatment of narcolepsy and other sleep disorders. Orexin receptor 3D structures have been solved [146, 144, 55, 126, 47, 109, 7, 145].\",\"PeriodicalId\":14617,\"journal\":{\"name\":\"IUPHAR/BPS Guide to Pharmacology CITE\",\"volume\":\"09 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IUPHAR/BPS Guide to Pharmacology CITE\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2218/gtopdb/f51/2023.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IUPHAR/BPS Guide to Pharmacology CITE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2218/gtopdb/f51/2023.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

食欲素受体(由NC-IUPHAR食欲素受体小组委员会商定的命名[43])由内源性多肽食欲素- a和食欲素- b(也称为下丘脑分泌素-1和-2;33和28aa)通过蛋白水解裂解和一些典型的肽修饰,由共同的前体,即食欲素前原或食欲素前体衍生而来[117]。食欲素信号与睡眠和清醒、奖励和成瘾、食欲和进食、疼痛门控、压力反应、焦虑和抑郁的调节有关。目前临床使用的食欲素受体配体有双重食欲素受体拮抗剂suvorexant、leborexant和daridorexant,用于催眠,几种双重和ox2选择性拮抗剂正在开发中。多种食欲素激动剂正在开发中,用于治疗嗜睡症和其他睡眠障碍。食欲素受体的三维结构已经被解决[146,144,55,126,47,109,7,145]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Orexin receptors in GtoPdb v.2023.1
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [43]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [117]. Orexin signaling has been associated with regulation of sleep and wakefulness, reward and addiction, appetite and feeding, pain gating, stress response, anxiety and depression. Currently the orexin receptor ligands in clinical use are the dual orexin receptor antagonists suvorexant and lemborexant and daridorexant, which are used as hypnotics, and several dual and OX2-selective antagonists are under development. Multiple orexin agonists are in development for the treatment of narcolepsy and other sleep disorders. Orexin receptor 3D structures have been solved [146, 144, 55, 126, 47, 109, 7, 145].
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
E3 ubiquitin ligase components in GtoPdb v.2023.2 Transient Receptor Potential channels (TRP) in GtoPdb v.2023.2 Lanosterol biosynthesis pathway in GtoPdb v.2023.1 Free fatty acid receptors in GtoPdb v.2023.1 Epithelial sodium channel (ENaC) in GtoPdb v.2023.1
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1